COVID-19 and Immune-Engaging Cancer Treatment

JAMA Oncology

EMBARGOED FOR RELEASE: 1 P.M. (ET), WEDNESDAY, MAY 20, 2020

Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2020.2367?guestAccessKey=94f1c911-3f85-480f-869f-39448d5a8056&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052020

 

What The Viewpoint Says: This Viewpoint discusses the challenges that arise for patients with cancer who are undergoing immune-engaging therapeutic treatment during the coronavirus disease 2019 (COVID-19) pandemic.

Authors: Muhammad Bilal Abid, M.D., M.R.C.P., of the Medical College of Wisconsin in Milwaukee, is the corresponding author.

 

(doi:10.1001/jamaoncol.2020.2367)

Editor’s Note: Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.